This is the seventh special EBMT report on the indications for haematopoietic stem cell
transplantation for haematological diseases, solid tumours and immune disorders. Our aim …

Monitoring of minimal residual disease (MRD) has become routine clinical practice in
frontline treatment of virtually all childhood acute lymphoblastic leukemia (ALL) and in many …

For over two decades, the EBMT has updated recommendations on indications for
haematopoietic cell transplantation (HCT) practice based on clinical and scientific …

We assessed minimal residual disease (MRD) detection and B-cell aplasia after
tisagenlecleucel therapy for acute lymphoblastic leukemia (ALL) to define biomarkers …

Drug sensitivity and resistance testing on diagnostic leukemia samples should provide
important functional information to guide actionable target and biomarker discovery. We …

Although hematopoietic stem-cell transplantation is widely performed in children with high-
risk acute lymphoblastic leukemia (ALL), the influence of donor types is poorly understood …

Introduction: Acute lymphoblastic leukemia (ALL) is the first neoplasm where the
assessment of early response to therapy by minimal residual disease (MRD) monitoring has …

Positive detection of minimal residual disease (MRD) by multichannel flow cytometry (MFC)
prior to hematopoietic cell transplantation (HCT) of patients with acute lymphoblastic …

Nowadays, minimal residual disease (MRD) is accepted as the strongest independent
prognostic factor in acute lymphoblastic leukemia (ALL). It can be detected by molecular …

Minimal residual disease (MRD) refers to a chemotherapy/radiotherapy-surviving leukemia
cell population that gives rise to relapse of the disease. The detection of MRD is critical for …